Tag Archives: Emerging Markets

Emerging Countries Closing in on Western R&D

By Jennifer Ringler | Published: November 10, 2010
UNESCO report reveals seismic shift in the world’s R&D balance. The US, Europe, and Japan may still be leading the global R&D effort, but emerging countries, especially China, are hot on their heels, says a UNESCO report launched yesterday (World Science Day). While investment in R&D is growing globally in volume, the emerging countries are rapidly [...]
Posted in Emerging Markets, Global, R&D | Also tagged , | 2 Comments

Report Reveals Global Supply Chain Fears

By Jennifer Ringler | Published: November 1, 2010
A new report published by Axendia is calling for better collaboration with suppliers, distributors, shippers, and regulators. Global pharmaceutical outsourcing has become increasingly prevalent, but is creating a complex and risky supply chain environment that has pharmaceutical and life sciences executives on high alert, according to a new study co-sponsored by PwC and published last [...]
Posted in Biotech, Emerging Markets, Global, Supply Chain | Also tagged , , , | Leave a comment

Big Pharma Reps Still Competing with Local Players in Emerging Markets

By Reid Paul | Published: September 15, 2010
Although pharma is an increasingly global marketplace, the relative rankings of companies are becoming more localized — with significant variations — according to a new Cegedim survey of physician attitudes towards reps in the major western markets and Brazil, India, Russia, and China. According to the International Rep Quality survey, physicians tend to favor domestic [...]
Posted in Emerging Markets, Europe, Guest Blog, Marketing, Sales | Also tagged , , , , , | Leave a comment

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment

US and Europe At Risk from Substandard Medicines

By Julian Upton | Published: February 25, 2010
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank. When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Posted in Biotech, Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety | Also tagged , , , , , , , , , , | Leave a comment